Navigation Links
Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
Date:7/5/2012

LONDON, July 5, 2012 /PRNewswire/ -- Patent expiry of key blockbuster atypical antipsychotic drugs is likely to cause a decline in growth of the European bipolar disorder therapeutics market until 2013. However, approval of new drugs and improved depot formulations are expected to present growth opportunities from 2014 to 2018.

New analysis from Frost & Sullivan (http://www.pharma.frost.com), Analysis of the European Bipolar-disorder Therapeutics Market, finds that the market earned revenues of $1.20 billion in 2011 and estimates this to reach approximately $1.22 billion in 2018, at a compound annual growth rate (CAGR) of 0.2 percent.

Patent expiry of several key blockbuster atypical antipsychotics, including Seroquel from AstraZeneca, the only approved atypical antipsychotic for both bipolar mania and depression, is one of the key challenges for the market participants.

"As generic equivalents of these blockbuster drugs reach the market, drug prices are expected to fall between 30-60 percent, causing an overall decrease of 10.1 percent in the European bipolar disorder therapeutics market until 2013," noted Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram.

Nonetheless, the high levels of unmet therapeutic needs present significant market opportunities and business potential. Over three million people have been diagnosed with some form (mania, hypomania or depression) of bipolar disorder in Europe; this number is estimated to double by 2018. Most of the currently approved drugs focus on the treatment of acute mania or hypomania, which means that drugs targeting bipolar depression are the need of the hour.

"Any initiative to develop new and improved drug formulations – particularly depot formulations of atypical antipsychotics that improves the efficacy, safety and overall performance of the drug – will bear fruit in the coming years," said Chi
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Frost & Sullivan Recognizes Siemens Healthcares CT Imaging Solution for the Value it Offers Both Service Providers and Patients
2. Frost & Sullivan: Label-Free Technology is a High Potential Market with Myriad Unexplored Applications
3. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
4. Need for Reduced Healthcare Outlays Creates Strong Growth Potential for Medical Imaging Services, Says Frost & Sullivan
5. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
6. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
7. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
8. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
9. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
10. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
11. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Health today reported fourth-quarter fiscal year 2015 revenues ... and non-GAAP diluted earnings per share (EPS) from ... percent. Non-GAAP operating earnings increased 33 percent to ... increased 44 percent to $558 million, and diluted ... $0.88. Fiscal year 2015 revenues increased ...
(Date:7/30/2015)... Ind., July 30, 2015 , Net Sales ... the prior year period and an increase of 5.7% constant ... second quarter was $(0.91), and adjusted earnings per share were ... , Company updates guidance Zimmer Biomet ... for the quarter ended June 30, 2015.  The Company reported ...
(Date:7/29/2015)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today ... Test v2 for Premarket Approval (PMA) to the ... companion diagnostic test for AZD9291, an AstraZeneca investigational ... an acquired resistant mutation.  Patients ... with tumor containing an EGFR sensitizing mutation show ...
Breaking Medicine Technology:Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 34Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 35Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 36
... Minn., Nov. 17, 2010 People who are searching ... with less potential for flushing can turn to Slo-Niacin®. ... Slo-Niacin® is a niacin supplement that has been shown ... "Slo-Niacin® features a unique patented polygel® system ...
... Sutro Biopharma today announced that the company has ... financing will support the company,s ongoing development of ... the company,s biochemical protein synthesis platform to meet ... Led by Skyline Ventures, the financing round, ...
Cached Medicine Technology:Slo-Niacin® Dietary Supplement Shown to Support 'Good' Cholesterol (HDL) 2Slo-Niacin® Dietary Supplement Shown to Support 'Good' Cholesterol (HDL) 3Slo-Niacin® Dietary Supplement Shown to Support 'Good' Cholesterol (HDL) 4Sutro Biopharma Secures $36.5 Million in Series C Financing 2
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students and ... Games, the largest sports and humanitarian event in the world this year and the ... Games, held July 25 through August 2, 2015, benefited from the participation of WesternU’s ...
(Date:7/30/2015)... Wisconsin (PRWEB) , ... July 30, 2015 , ... Quintessa ... Kybella is a nonsurgical treatment designed specifically for the elimination of ... one of the first locations in the state of Wisconsin to offer this innovative ...
(Date:7/30/2015)... ... July 30, 2015 , ... The New ... the New Jersey Department of Health, has received a $2.9 million grant from ... the U.S. Department of Health and Human Services (HHS). NJII will help the ...
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial and ... from the AC units and ventilation systems on hospital roofs. Bird droppings can carry ... virus. When these droppings dry, the fine powder can be carried into hospitals via ...
(Date:7/30/2015)... ... ... After conducting a nationwide executive search led by healthcare leadership solutions firm ... N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed his new ... Walsh is an expert in organizational change, physician development, implementation of quality and patient ...
Breaking Medicine News(10 mins):Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5
... sometimes a barrier for patients when it comes to ... barrier increases the risk that a patient will use ... suffer an adverse drug event. , , ScriptPro ... instructions and drug auxiliary warnings, and print them on ...
... receptors was shown to double survival time in mice, according ... phase animal model study were reported in the June 15 ... Care Medicine . Changes in genes encoding nicotine ... smoke, but with susceptibility to lung cancer. Nicotine exposure also ...
... issued today, the nonpartisan watchdog group Public Campaign Action Fund ... health care reform as "hazardous to America,s health, and a ... working families and small business owners in Kentucky." , ... Sen. McConnell,s opposition to health care legislation that includes a ...
... , Additional Group of Compounds and Enhanced Research Activities ... 8 Senetek PLC (OTC Bulletin Board: SNKTY), a ... technologies that target the science of healthy aging, announced ... agreement with the Czech Republic Institute of Experimental Botany ...
... Health Alliance Design Guidelines , , SAN RAMON, ... Alliance announced today that the Continua Health Alliance has ... local area network (LAN) standard. ZigBee Health Care offers ... single network. Continua recommends ZigBee for sensing and control ...
... Solution to Help Employees Lose Weight, Be Healthy and Save Money ... NTRI ), a leading provider of weight management products ... Nutrisystem Works(TM) program to companies and health plans across ... costs. The obesity epidemic continues to rise and studies have ...
Cached Medicine News:Health News:Robot Speaks Many Languages - Improves Pharmacy Patient Outcomes 2Health News:Defeating nicotine's double role in lung cancer 2Health News:Defeating nicotine's double role in lung cancer 3Health News:Watchdog Group Blasts McConnell for Putting Insurance Donors Before Health Care Reform 2Health News:Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 2Health News:Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 3Health News:ZigBee Selected by Continua Health Alliance for Next Generation Guidelines 2Health News:ZigBee Selected by Continua Health Alliance for Next Generation Guidelines 3Health News:New Nutrisystem Works(TM) Offers Corporate America New Weapon in the Fight Against Obesity 2Health News:New Nutrisystem Works(TM) Offers Corporate America New Weapon in the Fight Against Obesity 3Health News:New Nutrisystem Works(TM) Offers Corporate America New Weapon in the Fight Against Obesity 4